May 16 2012
Sorin Group, (Reuters Code: SORN.MI), a global medical device company
and a leader in the treatment of cardiovascular diseases, announces that
it received authorization from the Japanese Pharmaceuticals and Medical
Devices Agency (PMDA) to market its MEMO 3D Semi-Rigid Annuloplasty
Ring. The first MEMO 3D implant was performed at the Kobe City Medical
Center General Hospital.
Annuloplasty rings are indicated for repair of the mitral valve and are
designed to remodel the anatomical shape of the mitral annulus, thus
preventing further dilatation and minimizing the risk of late repair
failures.
Sorin's MEMO 3D Semi-Rigid Annuloplasty Ring is already marketed in
several European countries and in the United States.
The main features of Sorin's MEMO 3D Semi-Rigid Annuloplasty Ring
include:
-
An innovative cell-structure design, capable of mimicking the
physiological three-dimensional motility of the native mitral annulus
and accommodating the anatomical saddle shape;
-
A shape memory and super-elastic alloy core, aimed at restoring the
native shape and function;
-
Sorin's exclusive Carbofilm™ coating for enhanced hemo-compatibility;
-
Suture placement guides, a low profile holder and a special
configuration of the silicon filler for ease of implant.
Dr. Okada who successfully performed the first procedure of mitral valve
repair with MEMO 3D at the Kobe City Medical Center General Hospital
stated: "Due to its semi-rigid design and Carbofilm coating, MEMO 3D is
expected to provide continuous physiological motion of the mitral
annulus after mitral valve repair".
Prof. Fischlein (Klinikum Nürnberg, Nuremberg, Germany) who implanted
over 100 MEMO 3D rings reported: "We had the privilege of implanting
this semi-rigid ring for the first time in man. The MEMO 3D ring
capability to preserve mitral annulus flexibility has been confirmed by
our magnetic resonance images, obtained after more than 5 years
post-implantation, the longest follow-up period ever reported. We
recommend using a complete annuloplasty ring to mimic the physiological
three-dimensional motion of the native mitral annulus and preserve the
sphincter mechanism of the valve".
"We are extremely pleased to bring MEMO 3D unique technology to Japanese
cardiac surgeons and their patients", said Davide Bianchi, Sorin Group
President Heart Valve Business Unit. "Mitral valve repair has become the
therapy of choice for mitral valve disease and we believe that the MEMO
3D ring is the right solution for this type of procedure", he added.
Source: Sorin Group